Filing Flows › Beta Bionics (BBNX) › Q2 2026 › vs Q1 2026
Beta Bionics (BBNX) Q2 2026 vs Q1 2026 (quarter over quarter)
Beta Bionics's revenue rose $4.4M (+16%) from $27.6M in Q1 2026 to $32.0M in Q2 2026.
Beta Bionics, Q2 2026: revenue $32.0M (+38% year over year), operating margin -79.9%, net loss $23.4M, operating cash flow −$14.6M. The chart draws each line against Q1 2026, the increases inside each band.
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $32.0M | $27.6M | $4.4M | +16% |
| Other income, net | $2.2M | $2.4M | −$201K | -8% |
| Net loss | $23.4M | $21.9M | $1.5M | +7% |
| Costs & expenses | $57.6M | $51.9M | $5.7M | +11% |
| Operating costs | $57.6M | $51.9M | $5.7M | +11% |
| Cost of revenue | $13.1M | $11.2M | $1.9M | +17% |
| Research & development | $10.2M | $10.4M | −$116K | -1% |
| Sales & marketing | $24.6M | $20.7M | $3.9M | +19% |
| General & admin | $9.6M | $9.6M | −$17K | -0.2% |
| Operating cash sources | $23.4M | $21.9M | $1.5M | +7% |
| Depreciation | $709K | $585K | $124K | +21% |
| Share-based compensation | $7.0M | $5.4M | $1.6M | +30% |
| Working capital & other | $1.1M | −$7.9M | $9.0M | — |
| Cash used in operations | $14.6M | $23.8M | −$9.2M | -39% |
| Net loss absorbed | $23.4M | $21.9M | $1.5M | +7% |
Questions
How much did Beta Bionics's revenue grow quarter over quarter in Q2 2026?
Beta Bionics's revenue rose $4.4M (+16%) from $27.6M in Q1 2026 to $32.0M in Q2 2026.